Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations

References

• Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. 2000. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm. 49(2):99–102. doi: 10.1016/s0939-6411(99)00070-3.
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. 2001. Drug interaction studies with esomeprazole, the (s)-isomer of omeprazole. Clin Pharmacokinet. 40(7):523–537. doi: 10.2165/00003088-200140070-00004.
   PubMed Web of Science ®Google Scholar
• Babaei A, Bhargava V, Aalam S, Scadeng M, Mittal RK. 2009. Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 29(8):863–870. doi: 10.1111/j.1365-2036.2009.03947.x.
   PubMed Web of Science ®Google Scholar
• Badawy SI, Hussain MA. 2007. Microenvironmental pH modulation in solid dosage forms. J Pharm Sci. 96(5):948–959. doi: 10.1002/jps.20932.
   PubMed Web of Science ®Google Scholar
• Bavishi DD, Borkhataria CH. 2016. Spring and parachute: how cocrystals enhance solubility. Prog Cryst Growth Charact Mater. 62(3):1–8. doi: 10.1016/j.pcrysgrow.2016.07.001.
   Web of Science ®Google Scholar
• Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. 2022. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 10(9):2055. doi: 10.3390/biomedicines10092055.
   PubMed Web of Science ®Google Scholar
• Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S, Tony Zhou Q. 2021. Pharmaceutical amorphous solid dispersion: a review of manufacturing strategies. Acta Pharm Sin B. 11(8):2505–2536. doi: 10.1016/j.apsb.2021.05.014.
   PubMed Web of Science ®Google Scholar
• Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. 1997. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther. 19(5):1013–1023. doi: 10.1016/s0149-2918(97)80053-7.
   PubMed Web of Science ®Google Scholar
• Bremmell KE, Prestidge CA. 2019. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: opportunities and challenges. Drug Dev Ind Pharm. 45(3):349–358. doi: 10.1080/03639045.2018.1542709.
   PubMed Web of Science ®Google Scholar
• Brooks S, Phelan MP, Chand B, Hatem S. 2009. Markedly elevated lipase as a clue to diagnosis of small bowel obstruction after gastric bypass. Am J Emerg Med. 27(9):1167.e5–1167.e7. doi: 10.1016/j.ajem.2008.12.004.
   PubMedGoogle Scholar
• Cole S, Kerwash E, Andersson A. 2020. A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. Drug Metab Pharmacokinet. 35(1):2–11. doi: 10.1016/j.dmpk.2019.11.005.
   PubMed Web of Science ®Google Scholar
• Dajani EZ, Dajani NE, Shahwan TG. 2004. Over-the-counter drugs.
   Google Scholar
• de Villiers MM. 1996. Influence of agglomeration of cohesive particles on the dissolution behaviour of furosemide powder. Int J Pharm. 136(1–2):175–179. doi: 10.1016/0378-5173(95)04380-2.
   Google Scholar
• Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, et al. 2021. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 6(5):100231. doi: 10.1016/j.esmoop.2021.100231.
   PubMed Web of Science ®Google Scholar
• Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. 2019. Prediction of ARA/PPI drug-drug interactions at the drug discovery and development interface. J Pharm Sci. 108(1):87–101. doi: 10.1016/j.xphs.2018.10.032.
   PubMed Web of Science ®Google Scholar
• Dong Z, Li J, Wu F, Zhao P, Lee S-C, Zhang L, Seo P, Zhang L. 2020. Application of physiologically‐based pharmacokinetic modeling to predict gastric pH‐dependent drug–drug interactions for weak base drugs. CPT Pharmacometrics Syst Pharmacol. 9(8):456–465. doi: 10.1002/psp4.12541.
   PubMedGoogle Scholar
• Fadda HM, Hellström PM, Webb D-L. 2022. Intra-and inter-subject variability in gastric pH following a low-fat, low-calorie meal. Int J Pharm. 625:122069. doi: 10.1016/j.ijpharm.2022.122069.
   PubMedGoogle Scholar
• FDA, U.S. 2005. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.
   Google Scholar
• FDA, U.S. 2020. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications. https://www.fda.gov/media/144026/download.
   Google Scholar
• Gajewska M, Blumenstein L, Kourentas A, Mueller-Zsigmondy M, Lorenzo S, Sinn A, Velinova M, Heimbach T. 2020. Physiologically based pharmacokinetic modeling of oral absorption, pH, and food effect in healthy volunteers to drive alpelisib formulation selection. AAPS J. 22(6):134. doi: 10.1208/s12248-020-00511-7.
   PubMed Web of Science ®Google Scholar
• Garg V, Narang P, Taneja R. 2022. Antacids revisited: review on contemporary facts and relevance for self-management. J Int Med Res. 50(3):3000605221086457. doi: 10.1177/03000605221086457.
   Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwe KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9 (3):215–236. doi: 10.1038/nrd3028.
   Google Scholar
• Gigliobianco MR, Casadidio C, Censi R, Di Martino P. 2018. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 10(3):134. doi: 10.3390/pharmaceutics10030134.
   PubMed Web of Science ®Google Scholar
• Guo M, Sun X, Chen J, Cai T. 2021. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 11(8):2537–2564. doi: 10.1016/j.apsb.2021.03.030.
   PubMed Web of Science ®Google Scholar
• Gupta D, Bhatia D, Dave V, Sutariya V, Varghese Gupta S. 2018. Salts of therapeutic agents: chemical, physicochemical, and biological considerations. Molecules. 23(7):1719. doi: 10.3390/molecules23071719.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Repiso C, Moreno-Indias I, Tinahones FJ. 2021. Shifts in gut microbiota and their metabolites induced by bariatric surgery. Impact of factors shaping gut microbiota on bariatric surgery outcomes. Rev Endocr Metab Disord. 22(4):1137–1156. doi: 10.1007/s11154-021-09676-8.
   PubMed Web of Science ®Google Scholar
• Hintz RJ, Johnson KC. 1989. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 51(1):9–17. doi: 10.1016/0378-5173(89)90069-0.
   Web of Science ®Google Scholar
• IBRANCE® (palbociclib) capsules [prescribing information]. 2019. Pfizer Inc, New York, NY.
   Google Scholar
• Ingersoll KS, Cohen J. 2008. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 31(3):213–224. doi: 10.1007/s10865-007-9147-y.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Monma F, Ohishi K, Umino A, Suzuki K, Oka K, Kawakami K, Sekine T, Okuda M, Katayama N, et al. 2019. Evaluation of medication adherence and pharmacokinetics of dasatinib for earlier molecular response in Japanese patients with newly diagnosed chronic myeloid leukemia: a pilot study. Ther Drug Monit. 41(5):575–581. doi: 10.1097/FTD.0000000000000639.
   PubMed Web of Science ®Google Scholar
• Kambayashi A, Dressman JB. 2019. Predicting the changes in oral absorption of weak base drugs under elevated gastric pH using an in vitro–in silico–in vivo approach: case examples—dipyridamole, prasugrel, and nelfinavir. J Pharm Sci. 108(1):584–591. doi: 10.1016/j.xphs.2018.11.008.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Mitra A. 2015. Application of absorption modeling in rational design of drug product under quality-by-design paradigm. AAPS J. 17(5):1224–1236. doi: 10.1208/s12248-015-9781-1.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing—Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59(7):631–644. doi: 10.1016/j.addr.2007.05.003.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Vertzoni M, Reppas C. 2018. Physiologically based absorption modeling of salts of weak bases based on data in hypochlorhydric and achlorhydric biorelevant media. AAPS PharmSciTech. 19(7):2851–2858. doi: 10.1208/s12249-018-1059-3.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Wu Y. 2008. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 10(4):516–525. doi: 10.1208/s12248-008-9061-4.
   PubMed Web of Science ®Google Scholar
• Kim S, Bilgili E, Davé RN. 2021. Impact of altered hydro­phobicity and reduced agglomeration on dissolution of micronized poorly water-soluble drug powders after dry coating. Int J Pharm. 606:120853. doi: 10.1016/j.ijpharm.2021.120853.
   PubMedGoogle Scholar
• Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, et al. 2017. Biorelevant dissolution models for a weak base to facilitate formulation development and overcome reduced bioavailability caused by hypochlordyria or achlorhydria. Mol Pharm. 14(10):3577–3587. doi: 10.1021/acs.molpharmaceut.7b00593.
   PubMedGoogle Scholar
• Kuminek G, Salehi N, Waltz NM, Sperry DC, Greenwood DE, Hate SS, Amidon GE. 2023. Use of gastrointestinal simulator, mass transport analysis, and absorption simulation to investigate the impact of pH modifiers in mitigating weakly basic drugs’ performance issues related to gastric ph: palbociclib case study. Mol Pharm. 20(1):147–158. doi: 10.1021/acs.molpharmaceut.2c00545.
   PubMedGoogle Scholar
• Lahner E, Annibale B, Delle Fave G. 2009. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 29(12):1219–1229. doi: 10.1111/j.1365-2036.2009.03993.x.
   PubMed Web of Science ®Google Scholar
• Laine L, Hennekens C. 2010. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 105(1):34–41. doi: 10.1038/ajg.2009.638.
   Google Scholar
• Lam LH, Capparelli EV, Kurzrock R. 2016. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 78(2):427–432. doi: 10.1007/s00280-016-3087-6.
   PubMed Web of Science ®Google Scholar
• Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, Shi M. 2017. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 79(6):1119–1128. doi: 10.1007/s00280-017-3308-7.
   PubMed Web of Science ®Google Scholar
• Levêque D, Becker G, Bilger K, Natarajan-Amé S. 2020. Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet. 59(7):849–856. doi: 10.1007/s40262-020-00872-4.
   PubMed Web of Science ®Google Scholar
• Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. 2022. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective. Pharm Res. 39(8):1701–1731. doi: 10.1007/s11095-022-03274-2.
   PubMed Web of Science ®Google Scholar
• Litou C, Vertzoni M, Goumas C, Vasdekis V, Xu W, Kesisoglou F, Reppas C. 2016. Characteristics of the human upper gastrointestinal contents in the fasted state under hypo- and a-chlorhydric gastric conditions under conditions of typical drug – drug interaction studies. Pharm Res. 33(6):1399–1412. doi: 10.1007/s11095-016-1882-8.
   PubMed Web of Science ®Google Scholar
• Litou C, Vertzoni M, Xu W, Kesisoglou F, Reppas C. 2017. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: data in biorelevant media and in human aspirates. Eur J Pharm Biopharm. 115:94–101. doi: 10.1016/j.ejpb.2017.02.009.
   PubMed Web of Science ®Google Scholar
• Liu J, Nagapudi K, Dolton MJ, Chiang P-C. 2021. Utilizing tiny-TIM to assess the effect of acid-reducing agents on the absorption of orally administered drugs. J Pharm Sci. 110(8):3020–3026. doi: 10.1016/j.xphs.2021.04.017.
   PubMed Web of Science ®Google Scholar
• Lu T, Fraczkiewicz G, Salphati L, Budha N, Dalziel G, Smelick GS, Morrissey KM, Davis JD, Jin JY, Ware JA, et al. 2017. Combining “bottom-up” and “top-down” approaches to assess the impact of food and gastric pH on Pictilisib (GDC-0941) pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 6(11):747–755. doi: 10.1002/psp4.12228.
   PubMedGoogle Scholar
• Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. 1986. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci. 75(3):271–274. doi: 10.1002/jps.2600750313.
   PubMed Web of Science ®Google Scholar
• Mahjour M, Kesisoglou F, Cruanes M, Xu W, Zhang D, Maguire TJ, Rosen LA, Templeton AC, Kress MH. 2014. Effect of added alkalizer and surfactant on dissolution and absorption of the potassium salt of a weakly basic poorly water‐soluble drug. J Pharm Sci. 103(6):1811–1818. doi: 10.1002/jps.23985.
   PubMed Web of Science ®Google Scholar
• Malik SN, Canaham DH, Gouda MW. 1975. Effect of surfactants on absorption through membranes III: effects of dioctyl sodium sulfosuccinate and poloxalene on absorption of a poorly absorbable drug, phenolsulfonphthalein, in rats. J Pharm Sci. 64(6):987–990. doi: 10.1002/jps.2600640620.
   PubMed Web of Science ®Google Scholar
• McConnell EL, Basit AW, Murdan S. 2008. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol. 60(1):63–70. doi: 10.1211/jpp.60.1.0008.
   PubMed Web of Science ®Google Scholar
• Menning MM, Dalziel SM. 2013. Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound. Mol Pharm. 10(11):4005–4015. doi: 10.1021/mp400286s.
   PubMedGoogle Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 18(2):113–120. doi: 10.1016/s0928-0987(02)00251-8.
   PubMed Web of Science ®Google Scholar
• Miao L, Wu F, Yang X, Mousa YM, Ramamoorthy A, Lee S-C, Raines K, Zhang L, Seo P. 2022. Application of solubility and dissolution profile comparison for prediction of gastric pH-mediated drug-drug interactions. AAPS J. 24(1):35. doi: 10.1208/s12248-022-00684-3.
   PubMed Web of Science ®Google Scholar
• Miner PB, JR, Allgood LD, Grender JM. 2007. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment. Aliment Pharmacol Ther. 25(1):103–109. doi: 10.1111/j.1365-2036.2006.03129.x.
   PubMed Web of Science ®Google Scholar
• Mitra A, Kesisoglou F. 2013. Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development. Mol Pharm. 10(11):3970–3979. doi: 10.1021/mp400256h.
   PubMedGoogle Scholar
• Mitra A, Kesisoglou F, Beauchamp M, Zhu W, Chiti F, Wu Y. 2011. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect. Mol Pharm. 8(6):2216–2223. doi: 10.1021/mp200062a.
   PubMedGoogle Scholar
• Mitra A, Parrott N, Miller N, Lloyd R, Tistaert C, Heimbach T, Ji Y, Kesisoglou F. 2020. Prediction of pH-dependent drug-drug interactions for basic drugs using physiologically based biopharmaceutics modeling: industry case studies. J Pharm Sci. 109(3):1380–1394. doi: 10.1016/j.xphs.2019.11.017.
   PubMed Web of Science ®Google Scholar
• Monschke M, Wagner KG. 2019. Amorphous solid dispersions of weak bases with pH-dependent soluble polymers to overcome limited bioavailability due to gastric pH variability – an in-vitro approach. Int J Pharm. 564:162–170. doi: 10.1016/j.ijpharm.2019.04.034.
   PubMedGoogle Scholar
• Montenegro RC, Howarth A, Ceroni A, Fedele V, Farran B, Mesquita FP, Frejno M, Berger B-T, Heinzlmeir S, Sailem HZ, et al. 2020. Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. Oncotarget. 11(5):535–549. doi: 10.18632/oncotarget.27462.
   PubMedGoogle Scholar
• Moseson DE, Corum ID, Lust A, Altman KJ, Hiew TN, Eren A, Nagy ZK, Taylor LS. 2021. Amorphous solid dispersions containing residual crystallinity: competition between dissolution and matrix crystallization. AAPS J. 23(4):69. doi: 10.1208/s12248-021-00598-6.
   PubMed Web of Science ®Google Scholar
• Moseson DE, Taylor LS. 2023. Crystallinity: a complex critical quality attribute of amorphous solid dispersions. Mol Pharm. 20(10):4802–4825. doi: 10.1021/acs.molpharmaceut.3c00526.
   PubMedGoogle Scholar
• Nagar S, Radice C, Tuohy R, Stevens R, Bennyhoff D, Korzekwa K. 2023. The rat continuous intestine model predicts the impact of particle size and transporters on the oral absorption of glyburide. Mol Pharm. 20(1):219–231. doi: 10.1021/acs.molpharmaceut.2c00597.
   PubMedGoogle Scholar
• Nagy J, Van Boxtel CJ, Koopmans RP, Kager PA, Schipper HG, Butter JJ. 2000. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am J Tropical Med Hyg. 63(5):270–273. doi: 10.4269/ajtmh.2000.63.270.
   PubMed Web of Science ®Google Scholar
• Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 19(12):930–934. doi: 10.1021/ja02086a003.
   Google Scholar
• O’Dwyer PJ, Litou C, Box KJ, Dressman JB, Kostewicz ES, Kuentz M, Reppas C. 2019. In vitro methods to assess drug precipitation in the fasted small intestine – a PEARRL review. J Pharm Pharmacol. 71(4):536–556. doi: 10.1111/jphp.12951.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Echizen H. 2011. Clinically significant drug interactions with antacids: an update. Drugs. 71(14):1839–1864. doi: 10.2165/11593990-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Pace F, et al. 2007. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 3(3):363–379.
   PubMedGoogle Scholar
• Pandi P, Bulusu R, Kommineni N, Khan W, Singh M. 2020. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm. 586:119560. doi: 10.1016/j.ijpharm.2020.119560.
   PubMed Web of Science ®Google Scholar
• Pang J, Dalziel G, Dean B, Ware JA, Salphati L. 2013. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs – reversing the effect of elevated gastric pH with betaine HCl. Mol Pharm. 10(11):4024–4031. doi: 10.1021/mp400356m.
   PubMedGoogle Scholar
• Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E, Djebli N, Meneses-Lorente G. 2020. PBPK modeling on food and gastric pH changes on the pharmacokinetics of entrectinib. AAPS J. 22(4):78. doi: 10.1208/s12248-020-00463-y.
   PubMed Web of Science ®Google Scholar
• Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN. 2016. Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 18(6):1464–1474. doi: 10.1208/s12248-016-9957-3.
   PubMed Web of Science ®Google Scholar
• Patel D, Bertz R, Ren S, Boulton DW, Någård M. 2020. A systematic review of gastric acid-reducing agent-mediated drug–drug interactions with orally administered medications. Clin Pharmacokinet. 59(4):447–462. doi: 10.1007/s40262-019-00844-3.
   PubMed Web of Science ®Google Scholar
• Patel S, Zhu W, Xia B, Sharma N, Hermans A, Ehrick JD, Kesisoglou F, Pennington J. 2019. Integration of precipitation kinetics from an in vitro, multicompartment transfer system and mechanistic oral absorption modeling for pharmacokinetic prediction of weakly basic drugs. J Pharm Sci. 108(1):574–583. doi: 10.1016/j.xphs.2018.10.051.
   PubMed Web of Science ®Google Scholar
• Prescott L. 1972. Mechanisms of renal excretion of drugs (with special reference to drugs used by anaesthetists). Br J Anaesth. 44(3):246–251. doi: 10.1093/bja/44.3.246.
   PubMed Web of Science ®Google Scholar
• Rao C, Li M, Sun X, Li M, Lian X, Wang H, Jia L, Niu B, Li W. 2020. Preparation and characterization of phosphate-stabilized amorphous calcium carbonate nanoparticles and their application in curcumin delivery. Mater Chem Phys. 255:123552. doi: 10.1016/j.matchemphys.2020.123552.
   Web of Science ®Google Scholar
• Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE. 2021. Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using pH modifiers: a physiologically realistic mass transport analysis. Mol Pharm. 18(9):3326–3341. doi: 10.1021/acs.molpharmaceut.1c00262.
   PubMedGoogle Scholar
• Saravana Kumar K, Prasanna Raju SM. 2013. Y dissolution enhancement of poorly soluble drugs by using complexation technique – a review. J. Pharm. Sci. Res. 5(5):120–124.
   Google Scholar
• Schittny A, Philipp-Bauer S, Detampel P, Huwyler J, Puchkov M. 2020. Mechanistic insights into effect of surfactants on oral bioavailability of amorphous solid dispersions. J Control Release. 320:214–225. doi: 10.1016/j.jconrel.2020.01.031.
   PubMed Web of Science ®Google Scholar
• Schöller-Gyüre M, Kakuda TN, De Smedt G, Vanaken H, Bouche M-P, Peeters M, Woodfall B, Hoetelmans RMW. 2008. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 66(4):508–516. doi: 10.1111/j.1365-2125.2008.03214.x.
   PubMed Web of Science ®Google Scholar
• Segregur D, Mann J, Moir A, Karlsson EM, Dressman J. 2021. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling. Eur J Pharm Sci. 158:105656. doi: 10.1016/j.ejps.2020.105656.
   PubMed Web of Science ®Google Scholar
• Seibert KD. 2019. Milling operations in the pharmaceutical industry. Chemical Engineering in the Pharmaceutical Industry. p. 861–879.
   Google Scholar
• Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, de Jong A, Yu T, MacArthur HL, Majewski M, Ware JA, et al. 2021. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). Blood. 138(Supplement 1):4365–4365. doi: 10.1182/blood-2021-146610.
   Google Scholar
• Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M. 2003. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther. 18(11–12):1149–1157. doi: 10.1046/j.1365-2036.2003.01804.x.
   PubMed Web of Science ®Google Scholar
• Shugg T, Powell NR, Marroum PJ, Skaar TC, Younis IR. 2022. Evaluation of US food and drug administration drug label recommendations for coadministration of antivirals and acid-reducing agents. Clin Pharmacol Ther. 112(5):1088–1097. doi: 10.1002/cpt.2723.
   PubMed Web of Science ®Google Scholar
• Siegel IA, Gordon HP. 1986. Surfactant-induced alterations of permeability of rabbit oral mucosa in vitro. Exp Mol Pathol. 44(2):132–137. doi: 10.1016/0014-4800(86)90063-8.
   PubMed Web of Science ®Google Scholar
• Singh A, Van den Mooter G. 2016. Spray drying formulation of amorphous solid dispersions. Adv Drug Deliv Rev. 100:27–50. doi: 10.1016/j.addr.2015.12.010.
   PubMed Web of Science ®Google Scholar
• Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, et al. 2013. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 10(11):4055–4062. doi: 10.1021/mp400403s.
   PubMedGoogle Scholar
• Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O’Gorman M, Kirkovsky L, Kosa M, Wang D. 2017. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev. 6(6):614–626. doi: 10.1002/cpdd.356.
   PubMed Web of Science ®Google Scholar
• Sutton SC, Nause R, Gandelman K. 2017. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. AAPS J. 19(4):1084–1090. doi: 10.1208/s12248-017-0065-9.
   PubMed Web of Science ®Google Scholar
• Tartaglia N, Pavone G, Germano MP, Russo G, Pacilli M, Ambrosi A. 2022. Relationship between residual gastric area and weight loss after sleeve gastrectomy: a cohort study. Ann Med Surg (Lond). 73:103177. doi: 10.1016/j.amsu.2021.103177.
   PubMed Web of Science ®Google Scholar
• Tian Y, Fu N, Wu WD, Zhu D, Huang J, Yun S, Chen XD. 2014. Effects of co-spray drying of surfactants with high solids milk on milk powder wettability. Food Bioprocess Technol. 7(11):3121–3135. doi: 10.1007/s11947-014-1323-9.
   Web of Science ®Google Scholar
• Tolbert MK, Graham A, Odunayo A, Price J, Steiner JM, Newkirk K, Hecht S. 2017. Repeated famotidine administration results in a diminished effect on intragastric pH in dogs. J Vet Intern Med. 31(1):117–123. doi: 10.1111/jvim.14615.
   PubMed Web of Science ®Google Scholar
• Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. 1997. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 24(2):65–70. doi: 10.1097/00004836-199703000-00003.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 2023. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications: guidance for industry.
   Google Scholar
• Van Den Abeele J, Kostantini C, Barker R, Kourentas A, Mann JC, Vertzoni M, Beato S, Reppas C, Tack J, Augustijns P, et al. 2020. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo – in vitro investigation. Eur J Pharm Sci. 151:105377. doi: 10.1016/j.ejps.2020.105377.
   PubMed Web of Science ®Google Scholar
• Van den Mooter G. 2012. The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. Drug Discovery Today: Technologies. 9(2):e79–e85. doi: 10.1016/j.ddtec.2011.10.002.
   Google Scholar
• Vimalson DC. 2016. Techniques to enhance solubility of hydrophobic drugs: an overview. Asian Journal of Pharmaceutics (AJP). 10(2).
   Google Scholar
• Waller DG, Sampson AP. 2018. 33 – Dyspepsia and peptic ulcer disease. Medical Pharmacology and Therapeutics. 5th ed. Elsevier; p. 401–410.
   Google Scholar
• Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. 2011. Effect of pH and comedication on gastrointestinal absorption of posaconazole. Clin Pharmacokinet. 50(11):725–734. doi: 10.2165/11592630-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Walt RP, Gomes MD, Wood EC, Logan LH, Pounder RE. 1983. Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J (Clin Res Ed). 287(6384):12–14. doi: 10.1136/bmj.287.6384.12.
   PubMedGoogle Scholar
• Ware JA, Dalziel G, Jin JY, Pellett JD, Smelick GS, West DA, Salphati L, Ding X, Sutton R, Fridyland J, et al. 2013. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. Mol Pharm. 10(11):4074–4081. doi: 10.1021/mp4005595.
   PubMedGoogle Scholar
• Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. 1995. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis. 21(6):1431–1438. doi: 10.1093/clinids/21.6.1431.
   PubMed Web of Science ®Google Scholar
• Winnick S, Lucas DO, Hartman AL, Toll D. 2005. How do you improve compliance? Pediatrics. 115(6):e718–e724. doi: 10.1542/peds.2004-1133.
   PubMed Web of Science ®Google Scholar
• Wu D, Li M. 2023. Current state and challenges of physiologically based biopharmaceutics modeling (PBBM) in oral drug product development. Pharm Res. 40(2):321–336. doi: 10.1007/s11095-022-03373-0.
   PubMed Web of Science ®Google Scholar
• Wuelfing WP, El Marrouni A, Lipert MP, Daublain P, Kesisoglou F, Converso A, Templeton AC. 2022. Dose number as a tool to guide lead optimization for orally bioavailable compounds in drug discovery. J Med Chem. 65(3):1685–1694. doi: 10.1021/acs.jmedchem.1c01687.
   PubMed Web of Science ®Google Scholar
• Yin OQP, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H. 2010. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of Nilotinib. J Clin Pharmacol. 50(8):960–967. doi: 10.1177/0091270009346061.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu F, Lee SC, Zhao H, Zhang L. 2014. pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clin Pharmacol Ther. 96(2):266–277. doi: 10.1038/clpt.2014.87.
   PubMed Web of Science ®Google Scholar